August 2019—Hamilton Company and Enable Biosciences announced a collaboration to provide fully automated processing of up to 96 liquid biopsy samples at one time using a novel ultra-sensitive and highly specific immunoassay in a hands-free workflow. The immunoassay, available for research applications in type 1 diabetes, Lyme disease, allergy, and HIV testing, is intended to support development of early-stage treatment interventions to improve patient health and quality of life with reduced disease-related complications.
The qPCR-based assay technology developed by Enable Biosciences, known as antibody detection by agglutination PCR (ADAP), uses synthetic antigen-DNA conjugates to detect the presence of antibodies in liquid biopsy.
Hamilton’s Microlab Star automated workstation is available preconfigured and qualified to work with the type 1 diabetes ADAP assay, with the additional chemistry workflows to follow.
The Microlab Star optimized for the ADAP assay technology will be co-promoted by Hamilton and Enable Biosciences.
Hamilton, 775-858-3000
Enable Biosciences, 650-240-3105